Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease

Otology and Neurotology

Volumn 28, Issue 8, 2007, Pages 1140-1144

  Bodmer, Daniel ^a   Morong, Sharon ^b   Stewart, Craig ^b   Alexander, Ashlin ^b   Chen, Joseph M ^b   Nedzelski, Julian M ^b,c  

^a HNO Universitatsklinik   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Gentamicin; M ni re's disease

Indexed keywords

GENTAMICIN;

ADULT; ARTICLE; CALORIC VESTIBULAR TEST; CONTROLLED STUDY; ELECTRONYSTAGMOGRAPHY; FEMALE; FOLLOW UP; HEARING TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MENIERE DISEASE; OUTCOME ASSESSMENT; PERCEPTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; VERTIGO;

ADULT; ANTI-BACTERIAL AGENTS; CALORIC TESTS; DIZZINESS; DRUG IMPLANTS; EAR, MIDDLE; ELECTRONYSTAGMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENTAMICINS; HEARING TESTS; HUMANS; LONG-TERM CARE; MALE; MENIERE DISEASE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; VERTIGO;

EID: 36549076106     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31815aea05     Document Type: Article

References (28)

1. Thai-Van H, Bounaix MJ, Fraysse B. Ménière's disease. Pathophysiology and treatment. Drugs 2001;61:1089-102.
2. Schuknecht HH. Ablation therapy in the management of Méniè re's disease. Acta Otolaryngol 1957;132:1-42.
3. Rudnick MD, Ginsberg IA, Huber PS. Aminoglycosides ototoxicity following middle ear injection. Ann Otol Rhinol Laryngol 1980;89:1-9.
4. Park J, Cohen G. Vestibular ototoxicity in the chick: effects of streptomycin on equilibrium and on ampullary dark cells. Am J Otolaryngol 1982;6:117-27.
5. Pender D. Gentamicin tympanoclisis: effects on the vestibular secretory cells. Am J Otolaryngol 1985;6:358-67.
6. Beck C, Schmidt CL. Ten years experience with intratympanically applied streptomycin in the therapy of Morbus Ménière. Arch Otolaryngol 1978;221:149-52.
7. Nedzelski JM, Bryce GE, Pfleiderer AG. Treatment of Méniè re's disease with topical gentamicin: a preliminary report. J Otolaryngol 1992;21:94-101.
8. Schmidt CL, Beck C. Treatment of Morbus Ménière with intratympanically applied gentamicin. Laryngorhinootologie 1980;59:804-7.
9. Hirsch BE, Kamerer DB. Intratympanic gentamicin for Méniè re's disease. Am J Otol 1999;18:44-51.
10. Nedzelski JM, Schessel DA, Bryce GE, Pfleiderer AG. Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Ménière's disease. Am J Otol 1992;13:18-22.
11. Pearson PW, Brackmann DE. Committee on Hearing and Equilibrium guidelines for reporting treatment results in Ménière's disease. Otolaryngol Head Neck Surg 1985;93:579-81.
12. Jacobson GP, Newmann CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990;116:424-7.
13. Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. Laryngoscope 2003;113:815-20.
14. Hill SL, Digges EN, Silverstein H. Long-term follow-up after gentamicin application via the Silverstein MicroWick in the treatment of Ménière's disease. Ear Nose Throat J 2006;85:494-8.
15. Quaranta A, Scaringi A, Aloidi A, et al. Intratympanic therapy for Ménière's disease: effect of administration of low concentration of gentamicin. Acta Otolaryngol 2001;121:387-92.
16. Moller C, Odkvist LM, Thell J, et al. Vestibular and audiologic functions in gentamicin treated Ménière's disease. Am J Otol 1988;9:383-91.
17. Atlas J, Parnes LS. Intratympanic gentamicin for intractable Ménière's disease: 5-year follow-up. J Otolaryngol 2003;32:288-93.
18. Diamond C, O'Connell DA, Hornig JD, et al. Systematic review of intratympanic gentamicin in Ménière's disease. J Otolaryngol 2003;32:351-61.
19. Bamiou DE, Davies RA, McKee M, Luxon LM. The effect of severity of unilateral vestibular dysfunction on symptoms, disabilities, and handicap in vertigious patients. Clin Otolaryngol Allied Sci 1999;24:31-8.
20. Perez N, Garmendia I, Garcia-Granero M, Martin E, Garcia-Tapia R. Factor analysis and correlation between Dizziness Handicap Inventory and dizziness characteristics and impact on quality of life scales. Acta Otolaryngol Suppl 2001;545:145-54.
21. Quaranta A, Marini F, Sallustio V. Long-term outcome of Ménière's disease: endolymphatic mastoid shunt versus natural history. Audiol Neurotol 1998;3:54-60.
22. Commins D, Nedzelski J. Topical drugs in the treatment of Ménière's disease. Curr Opin Otolaryngol Head Neck Surg 1996;4:319-23.
23. Picciotti PM, Fiorita A, Di Nardo W, Quaranta N, Paludetti G, Maurizi M. VEMPs and dynamic posturography after intratympanic gentamicin in Ménière's disease. J Vestib Res 2005;15:161-8.
24. Lin FR, Migliaccio AA, Haslwanter T, Minor LB, Carey JP. Angular vestibulo-ocular reflex gains correlate with vertigo control after intratympanic gentamicin treatment for Ménière's disease. Ann Otol Rhinol Laryngol 2005;114:777-85.
25. Kaplan DM, Nedzelski JM, Al-Abidi A, Chen JM, Shipp DB. Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Ménière's disease. J Otolaryngol 2002;31:106-11.
26. Kaplan D, Nedzelski JM, Chen JM, Shipp DB. Intratympanic gentamicin for the treatment of unilateral Ménière's disease. Laryngoscope 2000;110:1298-305.
27. Ishiyama G, Lopez I, Baloh RW, Ishiyama A. Histopathology of the vestibular organ after intratympanic gentamicin failure for Méniè re's disease. Acta Otolaryngol 2007;127:34-40.
28. Kusunoki T, Cureoglu S, Schachern PA, et al. Effects of aminoglycoside administration on cochlear elements in human temporal bones. Auris Nasus Larynx 2004;31:383-8.